Advertisement
Advertisement
U.S. Markets open in 2 hrs 4 mins
Advertisement
Advertisement
Advertisement
Advertisement

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
26.31+0.41 (+1.58%)
At close: 04:00PM EST
25.43 -0.88 (-3.34%)
After hours: 04:31PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a rang

  • Simply Wall St.

    We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GuruFocus.com

    Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

    Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

Advertisement
Advertisement